EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Kardiovaskuläre, renale und Sicherheitsendpunkte unter GLP-1-Rezeptor-Agonisten allein und in Kombination mit SGLT2-Inhibitoren bei Typ-2-Diabetes: systematische Übersicht und Metaanalyse

Brendon L Neuen iD, Robert A Fletcher iD, Lauren Heath iD, Adam Perkovic iD, Muthiah Vaduganathan iD, Sunil V Badve iD, Katherine R Tuttle iD, Richard Pratley iD, Hertzel C Gerstein iD, Vlado Perkovic iD, Hiddo J L Heerspink iD

Circulation · 26.11.2024 · 150 (22) · 1781-1790

DOI: 10.1161/circulationaha.124.071689 ↗

Auf einen Blick

Die Metaanalyse zeigt bei Typ-2-Diabetes konsistente kardiovaskuläre und renale Effekte von GLP-1-Rezeptor-Agonisten unabhängig von SGLT2-Inhibitoren. Auch die Sicherheitsendpunkte unterschieden sich nicht.

Fragestellung

Unterscheiden sich die Effekte von GLP-1-Rezeptor-Agonisten bei Typ-2-Diabetes je nach begleitender SGLT2-Inhibitor-Therapie?

Methode

Systematische Übersicht und Metaanalyse randomisierter, doppelblinder, placebokontrollierter Outcome-Studien; Suche in MEDLINE und Embase bis 12. Juli 2024; Analyse nach Baseline-SGLT2-Inhibitor-Nutzung.

Ergebnisse

3 Studien mit 1743 von 17 072 (10,2 %) Teilnehmenden erhielten zu Beginn einen SGLT2-Inhibitor. MACE: HR 0,79 (95 %-KI 0,71–0,87); mit SGLT2-Inhibitor HR 0,77 (95 %-KI 0,54–1,09), ohne HR 0,79 (95 %-KI 0,71–0,87).

Schlussfolgerung der Autor:innen

Bei Menschen mit Typ-2-Diabetes sind die kardiovaskulären und renalen Vorteile von GLP-1-Rezeptor-Agonisten unabhängig vom SGLT2-Inhibitor-Gebrauch konsistent.

Kernaussagen

  • MACE unter GLP-1-Rezeptor-Agonisten reduziert
  • Effekte ähnlich mit und ohne SGLT2-Inhibitor
  • Auch renale und Sicherheitsendpunkte blieben vergleichbar

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Circulation, erschienen am 26.11.2024. Verfasst von Brendon L Neuen und 10 weiteren Autor:innen. Beteiligte Einrichtung: George Institute for Global Health (B.L.N., R.A.F., S.V.B., V.P., H.J.L.H.), University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 183-mal zitiert (Crossref) und nennt 30 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter 2) inhibitors both improve cardiovascular and kidney outcomes in people with type 2 diabetes. We conducted a systematic review and meta-analysis to assess the effects of GLP-1 receptor agonists on clinical outcomes with and without SGLT2 inhibitors. METHODS: We searched MEDLINE and Embase databases from inception until July 12, 2024, for randomized, double-blind, placebo-controlled outcome trials of GLP-1 receptor agonists in type 2 diabetes that reported treatment effects by baseline use of SGLT2 inhibitors, with findings supplemented by unpublished data. We estimated treatment effects by baseline SGLT2 inhibitor use using inverse variance-weighted meta-analysis. The main cardiovascular outcomes were major adverse cardiovascular events (nonfatal myocardial infarction, stroke, or cardiovascular death) and hospitalization for heart failure. Kidney outcomes included a composite of ≥50% reduction in estimated glomerular filtration rate, kidney failure or death caused by kidney failure, and annualized rate of decline in estimated glomerular filtration rate (estimated glomerular filtration rate slope). Serious adverse events and severe hypoglycemia were also evaluated. This meta-analysis was registered on the International Prospective Register of Systematic Reviews (PROSPERO; CRD42024565765). RESULTS: We identified 3 trials with 1743 of 17 072 (10.2%) participants with type 2 diabetes receiving an SGLT2 inhibitor at baseline. GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events by 21% (hazard ratio [HR], 0.79 [95% CI, 0.71–0.87]), with consistent effects in those receiving and not receiving SGLT2 inhibitors at baseline (HR, 0.77 [95% CI, 0.54–1.09] and HR, 0.79 [95% CI, 0.71–0.87], respectively; P -heterogeneity=0.78). The effect on hospitalization for heart failure was similarly consistent regardless of SGLT2 inhibitor use (HR, 0.58 [95% CI, 0.36–0.93] and HR, 0.73 [95% CI, 0.63–0.85]; P -heterogeneity=0.26). Effects on the composite kidney outcome (risk ratio, 0.79 [95% CI, 0.66–0.95]) and estimated glomerular filtration rate slope (0.78 mL/min/1.73 m 2 /y [95% CI, 0.57–0.98]) also did not vary according to SGLT2 inhibitor use ( P -heterogeneity=0.53 and 0.94, respectively). Serious adverse effects and severe hypoglycemia were also similar regardless of SGLT2 inhibitor use ( P -heterogeneity=0.29 and 0.50, respectively). CONCLUSIONS: In people with type 2 diabetes, the cardiovascular and kidney benefits of GLP-1 receptor agonists are consistent regardless of SGLT2 inhibitor use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesGlucagon-Like Peptide-1 Receptor AgonistsHumansKidneyTreatment OutcomeRandomized Controlled Trials as TopicGlomerular Filtration RateHypoglycemic Agents

Stichwörter der Autor:innen

cardiovascular diseasesdiabetes type 2glomerular filtration rateglucagon-like peptide-1 receptor agonistskidneyrenal insufficiency, chronicsodium glucose cotransporter 2treatment outcome

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • George Institute for Global Health (B.L.N., R.A.F., S.V.B., V.P., H.J.L.H.), University of New South Wales, Sydney, Australia.
  • Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N., L.H., A.P.).
  • Division of Cardiovascular Medicine, Center for Cardiometabolic Implementation Science, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.V.).
  • Department of Renal Medicine, St George Hospital, Sydney, Australia (M.V.).
  • Faculty of Medicine and Health (S.V.B.), University of New South Wales, Sydney, Australia.
  • Kidney Research Institute and Nephrology Division, University of Washington School of Medicine, Seattle (K.R.T.).

ORCID-Profile: Brendon L Neuen, Robert A Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil V Badve, Katherine R Tuttle, Richard Pratley, Hertzel C Gerstein, Vlado Perkovic, Hiddo J L Heerspink

Zitieren

APA

Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., & Heerspink, H. J. L. (2024). Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation, 150(22), 1781-1790. https://doi.org/10.1161/circulationaha.124.071689

Vancouver

Neuen BL, Fletcher RA, Heath L, Perkovic A, Vaduganathan M, Badve SV, et al. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation. 2024;150(22):1781-1790. doi:10.1161/circulationaha.124.071689

BibTeX
@article{Neuen2024,
  author = {Neuen, Brendon L and Fletcher, Robert A and Heath, Lauren and Perkovic, Adam and Vaduganathan, Muthiah and Badve, Sunil V and Tuttle, Katherine R and Pratley, Richard and Gerstein, Hertzel C and Perkovic, Vlado and Heerspink, Hiddo J L},
  title = {Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis},
  journal = {Circulation},
  year = {2024},
  volume = {150},
  number = {22},
  pages = {1781--1790},
  doi = {10.1161/circulationaha.124.071689}
}
Kostenlos starten →